Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015

Authors Bok RA

Published 8 February 2008 Volume 2008:4(1) Pages 79—85

DOI https://doi.org/10.2147/TCRM.S905



Robert A Bok

Department of Radiology, University of California at San Francisco, San Francisco, CA, USA

Abstract: The body’s immune system has some capacity to recognize and attack cancerous growths, including prostate cancer. However, various intrinsic characteristics of tumor cells usually limit that capacity. Therapeutically administered immunologic stimuli, such as APC8015, an individualized, ex vivo stimulation of a patient’s own antigen presenting cells (APC), are capable of boosting the anti-tumor response. Late phase clinical trials of APC8015 (now also called Sipuleucel-T) show evidence of slowing disease progression and increasing survival in advanced prostate cancer. Such immunotherapeutic approaches hold real promise to provide additional useful and welcome weapons against this common malignancy.

Keywords: prostate cancer, antigen presenting cells, immunologics

Creative Commons License © 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.